What's in Sara V. Latorre's pipeline?

Sara V. Latorre has 2 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Sara V. Latorre's portfolio?

Top competitors by shared drug class: Celgene, Celyad Oncology SA, Chongqing Precision Biotech Co., Ltd, EdiGene Inc., Gruppo Italiano Malattie EMatologiche dell'Adulto.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sara-v-latorre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sara V. Latorre — Portfolio Competitive Intelligence Brief

Sara V. Latorre pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celgene · 1 shared drug class
Celyad Oncology SA · 1 shared drug class
Chongqing Precision Biotech Co., Ltd · 1 shared drug class
EdiGene Inc. · 1 shared drug class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 shared drug class
Guangzhou Bio-gene Technology Co., Ltd · 1 shared drug class
Guangzhou Women and Children's Medical Center · 1 shared drug class
Beijing Yongtai Ruike Biotechnology Company Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sara V. Latorre:

Cite this brief

Drug Landscape (2026). Sara V. Latorre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sara-v-latorre. Accessed 2026-05-16.